#AANAM – Ocrevus, Rituximab Linked to More Severe COVID-19 Cases in Italy

#AANAM – Ocrevus, Rituximab Linked to More Severe COVID-19 Cases in Italy

292944

#AANAM – Ocrevus, Rituximab Linked to More Severe COVID-19 Cases in Italy

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Disease-modifying therapies (DMTs) that target CD20 are associated with worse outcomes from COVID-19 in multiple sclerosis (MS) patients, an analysis of patient data from Italy suggests. Conversely, interferon-based DMTs and Aubagio (teriflunomide) were associated with less severe COVID-19 cases in the analysis. These findings were shared in the presentation,…

You must be logged in to read/download the full post.